Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beta alethine - Dovetail Technologies

Drug Profile

Beta alethine - Dovetail Technologies

Alternative Names: Alethine beta; Ax-101; Beta LT; Betathine

Latest Information Update: 15 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of New Mexico
  • Developer LifeTime Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued Lymphoma; Macroglobulinaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Apr 2021 Pharmacodynamics data from a preclinical study in solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
  • 01 Apr 2021 Preclinical trials in Solid tumours in USA (unspecified route), before April 2021
  • 30 Apr 2002 LifeTime Pharmaceuticals has acquired all the intellectual property covering beta alethine from Dovetail
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top